Gulley JL - Search Results

1

Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, Madan RA, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL. Turkbey B, et al. Among authors: gulley jl. AJR Am J Roentgenol. 2020 Jan;214(1):105-113. doi: 10.2214/AJR.19.21264. Epub 2019 Oct 15. AJR Am J Roentgenol. 2020. PMID: 31613660 Free PMC article. Clinical Trial.

2

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

3

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

4

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

5

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Behrens RJ, Gulley JL, Dahut WL. Behrens RJ, et al. Among authors: gulley jl. Am J Ther. 2003 May-Jun;10(3):228-32. doi: 10.1097/00045391-200305000-00011. Am J Ther. 2003. PMID: 12756431

6

The emerging role of bisphosphonates in prostate cancer.

Posadas EM, Dahut WL, Gulley J. Posadas EM, et al. Am J Ther. 2004 Jan-Feb;11(1):60-73. doi: 10.1097/00045391-200401000-00012. Am J Ther. 2004. PMID: 14704597 Review.

7

Novel therapeutic strategies in prostate cancer.

Retter AS, Gulley JL, Dahut WL. Retter AS, et al. Among authors: gulley jl. Cancer Biol Ther. 2004 Apr;3(4):371-6. doi: 10.4161/cbt.3.4.725. Epub 2004 Apr 29. Cancer Biol Ther. 2004. PMID: 14726702 Free article. Review.

8

Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.

Gulley J, Dahut WL. Gulley J, et al. Urology. 2003 Dec 29;62 Suppl 1:147-54. doi: 10.1016/j.urology.2003.08.003. Urology. 2003. PMID: 14747053 Review.

9

National Cancer Institute intramural approach to advanced prostate cancer.

Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. Arlen PM, et al. Clin Prostate Cancer. 2002 Dec;1(3):153-62. doi: 10.3816/cgc.2002.n.017. Clin Prostate Cancer. 2002. PMID: 15046690

10

Novel clinical trials in androgen-independent prostate cancer.

Gulley J, Dahut W. Gulley J, et al. Clin Prostate Cancer. 2002 Jun;1(1):51-7. doi: 10.3816/cgc.2002.n.007. Clin Prostate Cancer. 2002. PMID: 15046713 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters